Adial Pharmaceuticals, Inc. (ADIL)
After hours:
| Previous Close | 1.4500 |
| Open | 1.4900 |
| Bid | 1.4200 x 200 |
| Ask | 1.4600 x 200 |
| Day's Range | 1.4300 - 1.5300 |
| 52 Week Range | 0.7700 - 14.0000 |
| Volume | |
| Avg. Volume | 4,036,993 |
| Market Cap | 6.138M |
| Beta (5Y Monthly) | 1.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.9800 |
| Earnings Date | Aug 19, 2024 - Aug 23, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireAdial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City. Cary Claiborne, President and Chief Executive Officer of Adial, is scheduled to present
- GlobeNewswire
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2024. Cary Claiborne, President and Chief Executive Officer of Adial, stated, “We are making steady progress as it relates to AD04. We have in
- GlobeNewswire
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office. This patent expands Adial’s intellectual property protection and covers the combination of the Company’s proprietary g
